文献速递瘢痕与激光创面修复美容整形

A型肉毒毒素用于甲状腺切除术后创面愈合的随机对照研究

The Use of Botulinum Toxin Type A in the Healing of Thyroidectomy Wounds: A Randomized, Prospective, Placebo-Controlled Study.
PubMed 文献 · Plast Reconstr Surg · 2019-01-01

双盲随机对照试验纳入40例甲状腺手术患者,切口半侧注射A型肉毒毒素、另半侧注射生理盐水,术后4周、6个月、1年评估瘢痕。总体两侧瘢痕无显著差异,但瘢痕史严重者6个月时肉毒毒素侧瘢痕显著减轻。结论与同类设计研究相反,需进一步研究。

要点

  • 甲状腺切口闭合后即刻注射A型肉毒毒素,总体瘢痕结局与对照侧无差异。
  • 瘢痕史严重者术后6个月肉毒毒素侧瘢痕显著减轻。
  • 证据等级为治疗性II级,结果与同类设计研究相反。

核心结论

  • 甲状腺切口闭合后即刻注射A型肉毒毒素与对照侧相比瘢痕结局无差异。
  • 瘢痕史严重者肉毒毒素侧术后6个月瘢痕显著减轻。
  • 本研究结果与同类设计研究相反,需进一步研究确定A型肉毒毒素的最佳用法。

研究设计与样本

  • 双盲、随机、对照试验,共纳入40例患者。
  • 患者均经标准化切口行全甲状腺切除、甲状腺次全切除或甲状旁腺切除。
  • 切口半侧注射A型肉毒毒素,另半侧注射生理盐水安慰剂。
  • 术后4周、6个月、1年用主观瘢痕分析量表评估。
  • 术前调查评估瘢痕史。

主要发现

  • 各时间点A型肉毒毒素侧与安慰剂侧瘢痕无显著差异。
  • 亚组分析显示瘢痕史严重者术后6个月肉毒毒素侧瘢痕显著减轻。

临床怎么用

  • 甲状腺切口常规即刻注射A型肉毒毒素改善瘢痕的证据不足。
  • 对瘢痕史严重患者可考虑使用,但需结合个体情况并进一步研究验证。

局限性

  • 样本量40例,亚组分析样本更小。
  • 采用主观瘢痕分析量表评估。
  • 结果与同类设计研究相反,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent research has indicated that botulinum toxin type A may have an inhibitory effect on the formation of fibroblasts and thus possibly decreases the severity of scar formation. Therefore, a trial was designed to assess the effects of botulinum toxin type A on scar formation after thyroid surgery. METHODS: A double-blind, randomized, controlled trial was designed. All patients underwent a preoperative survey to assess scar history. All patients underwent a total thyroidectomy, hemithyroidectomy, or parathyroidectomy through a standardized incision. At the conclusion of the case, one half of the incision was injected with botulinum toxin type A, and the other half was injected with saline (placebo). The scars were then evaluated at 4 weeks, 6 months, and 1 year postoperatively using subjective scar analysis scales. RESULTS: A total of 40 patients were enrolled. There was no significant difference in scarring at any of the time points between the botulinum toxin type A-treated and placebo sides of the incision. A subgroup analysis was performed that examined the effects of botulinum toxin type A on those with a severe scar history. This demonstrated a significant decrease in scarring at 6 months postoperatively on the botulinum toxin type A-treated side. CONCLUSIONS: This study indicates that botulinum toxin type A administration immediately after surgical closure of a thyroid incision does not demonstrate a difference in scar outcomes compared with the control side. However, there was less scarring in subjects who had a severe scar history. This study found opposite results to a similarly designed study. Further study is required to determine the optimal use of botulinum toxin type A for wound healing. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, II.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Phillips TJ, Fung E, Rigby MH, et al. The Use of Botulinum Toxin Type A in the Healing of Thyroidectomy Wounds: A Randomized, Prospective, Placebo-Controlled Study. Plast Reconstr Surg. 2019. PMID: 30688903. doi:10.1097/PRS.0000000000005264

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。